— Know what they know.
Not Investment Advice
Also trades as: BDX (NYSE) · $vol 428M · BDXB (NYSE) · $vol 22M · BDX.SW (SIX) · BDXA (NYSE)

0R19.L LSE

Becton, Dickinson and Company
1W: -1.2% 1M: -8.0% 3M: -17.2% YTD: -14.4% 1Y: -34.4% 3Y: -33.7% 5Y: -37.5%
$147.33
+0.44 (+0.30%)
 
Weekly Expected Move ±5.2%
$128 $135 $143 $150 $158
LSE · Healthcare · Medical - Instruments & Supplies · Alpha Radar Sell · Power 45 · $41.9B mcap · 275M float · 0.0014% daily turnover
Smart Money Score
No convergence signal
Key Statistics
Market Cap$41.9B
52W Range141.96-286.33
Volume306
Avg Volume3,814
Beta0.28
Dividend$49.54
Analyst Ratings
14 Buy 17 Hold 1 Sell
Consensus Hold
Company Info
CEOThomas E. Polen Jr.
Employees70,000
SectorHealthcare
IndustryMedical - Instruments & Supplies
IPO Date2014-11-05
Websitebd.com
1 Becton Drive
Franklin Lakes, NJ 07417-1880
US
201 847 6800
About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

Latest News
No recent news

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms